<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542165</url>
  </required_header>
  <id_info>
    <org_study_id>L_8819</org_study_id>
    <nct_id>NCT00542165</nct_id>
  </id_info>
  <brief_title>Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy</brief_title>
  <official_title>Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect under daily practice conditions, clinical data on the changes of sexual function
      when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with
      lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IIEF and GEQ (Global Efficacy Question)</measure>
    <time_frame>at intermediate visit (M1) and at end-point visit(M3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure and heart rate measure in sitting position</measure>
    <time_frame>at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS and Quality of Life Score</measure>
    <time_frame>at intermediate visit (M1) and at end-point visit(M3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate and post voiding residual urine</measure>
    <time_frame>at end-point visit(M3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous reported adverse events</measure>
    <time_frame>During all the study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">166</enrollment>
  <condition>BPH/LUTS/Sexual Functions</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male patients suffering from LUTS lasting 6months and over

          -  male patients aged 50 years old and over who has a continuous active partner

        Exclusion Criteria:

          -  Primary hypogonadism and neuropathy patients

          -  History of prostate surgery

          -  Patients with prostate cancer

          -  History of organ surgery or organ damage in pelvis

          -  History of myocardiac infarction, stroke, and life threatening arrythmia within last 6
             months

          -  Patients with haematuria caused by other reasons except BPH

          -  Patients with uncontrolled hypertension in spite of treatment with antihypertensive
             agents

          -  History of a malignant tumor within last 5 years

          -  Patients who are currently controlled with other medication for erectile dysfunction

          -  Patients who have been administered with androgen or antiandrogen

          -  Patients who is treated for psychiatric disorder or depression

          -  Combination with other alpha1-blockers

          -  Patients previously not improved by an alpha1-blocker treatment

          -  Known hypersensitivity to the alfuzosin

          -  History of postural hypotension or syncope

          -  Hepatic insufficiency

          -  Unstable angina pectoris

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Young Ahn</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>October 10, 2007</last_update_submitted>
  <last_update_submitted_qc>October 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

